Phase 3 TBA
Amp Volatility Score
Catalyst Info & Data Links
TITLE: Oral Korsuva in Pruritus CKD 3-5
WHAT IS THE CATALYST EVENT?
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
Phase 2 Topline Results - Oral KORSUVATM for CKD-associated Pruritus
05-2020: Corporate Presentation (slide 29)
~7.3 million diagnosed with CKD (IQVIA est)
source - slide 3
MECHANISM OF ACTION / RATIONALE
Difelikefalin (CR845) is a peripherally restricted, selective kappa opioid receptor agonist that exerts antipruritic effects by means of activation of kappa opioid receptors on peripheral neurons and immune cells. The hydrophilic small-peptide structure restricts passive diffusion across membranes, thereby limiting access to kappa opioid receptors in the central nervous system (Fishbane et al., 2020).
Updated by HC
CARA, Korsuva IV (CR845 IV), Pruritus, CKD
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See What The Community Is Saying - Click To See Full Post